Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2018	Jun. 30, 2018
Series M Preferred Stock
STOCKHOLDER'S EQUITY
Preferred Stock, $0.0001 par value Authorized 50,000,000 as of September 30, 2018 and June 30, 2018; Series M Preferred Stock, $0.0001 par, Authorized 10,000,000 as of September 30, 2018 and June 30,2018 9,000,000 shares outstanding as of September 30, 2018 and June 30, 2018 Respectively; Series AA Preferred Stock, $0.0001 par, Authorized 1,000,000 200 and 200 shares outstanding as of September 30, 2018 and June 30, 2018 , respectfully	$ 900	$ 900
Series AA Preferred Stock
STOCKHOLDER'S EQUITY
Preferred Stock, $0.0001 par value Authorized 50,000,000 as of September 30, 2018 and June 30, 2018; Series M Preferred Stock, $0.0001 par, Authorized 10,000,000 as of September 30, 2018 and June 30,2018 9,000,000 shares outstanding as of September 30, 2018 and June 30, 2018 Respectively; Series AA Preferred Stock, $0.0001 par, Authorized 1,000,000 200 and 200 shares outstanding as of September 30, 2018 and June 30, 2018 , respectfully	0	0
Audited
CURRENT ASSETS
Cash		370,313
Prepaid Expenses, Related Parties		66,239
Prepaid Expenses		650
Due From Related Party		35,000
Due From Third Party
Total Current Assets		472,202
Convertible Note Receivable, Related Party
Investment Securities, Related Party
Total Other Assets
Total Assets		472,202
Current Liabilities:
Accounts Payable		1,087,969
Accrued Expenses		11,593
Total Current Liabilities		1,099,562
Total Liabilities		1,099,562
STOCKHOLDER'S EQUITY
Common Stock, Authorized 100,000,000, $0.0001 Par Value 4,758,001 shares and 6,033,001 shares issued and outstanding as of June 30, 2018 and September 30, 2018 respectively		475
Preferred Stock, $0.0001 par value Authorized 50,000,000 as of September 30, 2018 and June 30, 2018; Series M Preferred Stock, $0.0001 par, Authorized 10,000,000 as of September 30, 2018 and June 30,2018 9,000,000 shares outstanding as of September 30, 2018 and June 30, 2018 Respectively; Series AA Preferred Stock, $0.0001 par, Authorized 1,000,000 200 and 200 shares outstanding as of September 30, 2018 and June 30, 2018 , respectfully
Common Stock subscribed for but unissued , 100000 and 0 shares as of June 30, 2018 and September 30, 2018 respectively		100,000
Additional Paid In Capital		1,620,689
Contributed Capital, Related Party		413,878
Accumulated Deficit		(2,763,302)
Total Stockholder's Deficit		(627,358)
TOTAL LIABILITIES AND STOCKHOLDER'S EQUITY		$ 472,202
as restated
CURRENT ASSETS
Cash	301,906
Prepaid Expenses, Related Parties	38,814
Prepaid Expenses	7,127
Due From Related Party
Due From Third Party	7,100
Total Current Assets	354,947
Convertible Note Receivable, Related Party	350,000
Investment Securities, Related Party	61,250
Total Other Assets	411,250
Total Assets	766,197
Current Liabilities:
Accounts Payable	1,355,591
Accrued Expenses	8,435
Total Current Liabilities	1,364,026
Total Liabilities	1,364,026
STOCKHOLDER'S EQUITY
Common Stock, Authorized 100,000,000, $0.0001 Par Value 4,758,001 shares and 6,033,001 shares issued and outstanding as of June 30, 2018 and September 30, 2018 respectively	603
Preferred Stock, $0.0001 par value Authorized 50,000,000 as of September 30, 2018 and June 30, 2018; Series M Preferred Stock, $0.0001 par, Authorized 10,000,000 as of September 30, 2018 and June 30,2018 9,000,000 shares outstanding as of September 30, 2018 and June 30, 2018 Respectively; Series AA Preferred Stock, $0.0001 par, Authorized 1,000,000 200 and 200 shares outstanding as of September 30, 2018 and June 30, 2018 , respectfully
Common Stock subscribed for but unissued , 100000 and 0 shares as of June 30, 2018 and September 30, 2018 respectively
Additional Paid In Capital	2,534,688
Contributed Capital, Related Party	413,878
Accumulated Deficit	(3,547,898)
Total Stockholder's Deficit	(597,829)
TOTAL LIABILITIES AND STOCKHOLDER'S EQUITY	$ 766,197

Zander Therapeutics, Inc 10-Q/A